Market Cap 200.75B
Revenue (ttm) 46.79B
Net Income (ttm) 15.51B
EPS (ttm) N/A
PE Ratio 11.01
Forward PE 12.82
Profit Margin 33.14%
Debt to Equity Ratio 0.72
Volume 10,790,900
Avg Vol 16,685,893
Day's Range N/A - N/A
Shares Out 4.47B
Stochastic %K 35%
Beta 0.77
Analysts Sell
Price Target $46.76

Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The c...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 45 44 44 88 88
Address:
Novo Alle 1, Bagsvaerd, Denmark
Hooooooold
Hooooooold May. 24 at 9:35 PM
$NVO the pill is going to be big for locations with weak cold chain storage.
0 · Reply
TradingNode
TradingNode May. 24 at 9:32 PM
$NVO A recent development from last week highlights Novo Nordisk’s expanding long-term healthcare footprint in Algeria. With support from Danish diplomacy, Novo met with Algeria’s Ministry of Health to discuss broader cooperation beyond its existing partnership with state-owned pharma company Saidal. The discussions covered diabetes and obesity prevention, early screening and diagnosis of chronic diseases, healthcare digitization (electronic medical records and telemedicine), and strengthening local healthcare infrastructure. Last year, Novo already signed a strategic agreement with Saidal focused on the production and distribution of innovative treatments, including next-generation insulins. Algeria has a population of ~48M, with an estimated 27% obesity rate, positioning it as a potentially meaningful long-term market amid rising global metabolic disease prevalence. The focus is gradually shifting from single product exposure to broader healthcare system penetration.
0 · Reply
capitalthinktank
capitalthinktank May. 24 at 2:51 PM
$NVO is increasing its collaboration with Egypt’s Healthcare Authority in preparation for Phase 2 of the country’s universal health insurance rollout. The partnership will target obesity, diabetes, fatty liver disease, and rare blood disorders such as hemophilia, while also strengthening prevention and early detection initiatives for chronic conditions. Novo and Egypt’s Healthcare Authority are further expanding training programs for physicians, nurses, and pharmacists, aligned with global treatment standards. Minya Governorate is set to be the first region in Phase 2, identified as a key focus area due to its large population and the need for greater awareness and training efforts. The two sides also reviewed ongoing hemophilia programs in Ismailia and Aswan, with plans to extend them to Luxor.
0 · Reply
MaikbestTV
MaikbestTV May. 24 at 11:50 AM
$NVO new positive bullish Novo Nordisk could be setting up for a major comeback. 🚀 Strong early demand for the new oral Wegovy pill, millions of prescriptions already, and Europe moving closer to approval. The obesity market is still massive and growing fast. If the pill keeps scaling, this could completely shift sentiment around $NVO again. Bulls are starting to come back. 👀
0 · Reply
Baxter5
Baxter5 May. 24 at 8:26 AM
$NVO nice base being built at the 44 doller
0 · Reply
JIMMYRIZZ
JIMMYRIZZ May. 24 at 6:17 AM
0 · Reply
JIMMYRIZZ
JIMMYRIZZ May. 24 at 3:43 AM
0 · Reply
clan
clan May. 23 at 10:53 PM
$MNKD $LLY $NVO Type 1 diabetic and highly-favored Indycar driver, Conor Daly, will be driving the #23 car🏎 at the 500 on Sunday afternoon. 😙🧱 A win🏁, a puff of Afrezza, and then drinking the milk🥛. For the good of all Mannkind.
0 · Reply
Hooooooold
Hooooooold May. 23 at 9:02 PM
$NVO copied from reddit post >> 6 full weeks after Foundayo’s launch (and 5.5 weeks after broad pharmacy availability), the Wegovy pill has a >97% US market share, selling 42 pills for every time Lilly sells 1. That is incredibly impressive - “winner takes it all” dynamics.
1 · Reply
Hooooooold
Hooooooold May. 23 at 6:52 PM
$NVO it would be pretty crazy if the EU blocks or delays foundayo approval a year or two.
2 · Reply
Latest News on NVO
Wegovy Approval Boosts Novo Nordisk (NVO) Stock by 2.4%

2026-05-22T20:37:38.000Z - 2 days ago

Wegovy Approval Boosts Novo Nordisk (NVO) Stock by 2.4%


Novo Nordisk uses AI to fast-track drug launches, expand India role

Fri, 22 May 2026 09:11:22 -0400 - 2 days ago

Novo Nordisk uses AI to fast-track drug launches, expand India role


European Regulator Backs Novo Nordisk's Wegovy Weight-Loss Pill

Fri, 22 May 2026 08:30:00 -0400 - 2 days ago

European Regulator Backs Novo Nordisk's Wegovy Weight-Loss Pill


Best Weight Loss Drug Stocks to Buy in 2026

Wed, 20 May 2026 23:15:00 -0400 - 3 days ago

Best Weight Loss Drug Stocks to Buy in 2026


3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now

Mon, 18 May 2026 12:00:00 -0400 - 6 days ago

3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now


US Supreme Court rebuffs pharma challenge to Biden-era drug price

Mon, 18 May 2026 09:44:10 -0400 - 6 days ago

US Supreme Court rebuffs pharma challenge to Biden-era drug price


Novo Nordisk A/S - share repurchase programme

Mon, 18 May 2026 09:38:00 -0400 - 6 days ago

Novo Nordisk A/S - share repurchase programme


Novo Nordisk Eyes Global Push for Wegovy Pill

2026-05-18T06:48:55.000Z - 6 days ago

Novo Nordisk Eyes Global Push for Wegovy Pill


Novo Nordisk's next obesity battlefront: Winning beyond America

Mon, 18 May 2026 01:00:01 -0400 - 6 days ago

Novo Nordisk's next obesity battlefront: Winning beyond America


Buy, Sell, or Hold Novo Nordisk at $46?

Fri, 15 May 2026 10:45:00 -0400 - 9 days ago

Buy, Sell, or Hold Novo Nordisk at $46?


Best Healthcare Stocks to Buy in 2026

2026-05-14T18:45:00.000Z - 10 days ago

Best Healthcare Stocks to Buy in 2026


Is Novo Nordisk's Rebound for Real--or Just a Head Fake?

Wed, 13 May 2026 13:15:00 -0400 - 11 days ago

Is Novo Nordisk's Rebound for Real--or Just a Head Fake?


Novo Nordisk A/S Q1 Earnings Call Highlights

Wed, 13 May 2026 05:07:10 -0400 - 11 days ago

Novo Nordisk A/S Q1 Earnings Call Highlights


Novo Nordisk A/S Q1 Earnings Call Highlights

2026-05-13T09:06:38.000Z - 11 days ago

Novo Nordisk A/S Q1 Earnings Call Highlights


Mixed options sentiment in Novo Nordisk with shares up 1.26%

2026-05-12T20:51:40.000Z - 12 days ago

Mixed options sentiment in Novo Nordisk with shares up 1.26%

NVO


Hims & Hers Health Q1 Earnings Call Highlights

2026-05-12T04:04:08.000Z - 12 days ago

Hims & Hers Health Q1 Earnings Call Highlights


NVO: Novo Nordisk Shows Bullish Activity with Stock Uptick

2026-05-11T23:22:34.000Z - 13 days ago

NVO: Novo Nordisk Shows Bullish Activity with Stock Uptick


Bullish flow in Novo Nordisk with shares up 0.68%

2026-05-11T21:14:05.000Z - 13 days ago

Bullish flow in Novo Nordisk with shares up 0.68%


Novo Nordisk beats profit forecasts on bumper Wegovy pill sales

May 6, 2026, 11:36 AM EDT - 18 days ago

Novo Nordisk beats profit forecasts on bumper Wegovy pill sales


Novo Raises Forecast as Wegovy Pill Fuels Sales

May 6, 2026, 8:36 AM EDT - 18 days ago

Novo Raises Forecast as Wegovy Pill Fuels Sales


Novo Nordisk Earnings Call Transcript: Q1 2026

May 6, 2026, 7:00 AM EDT - 18 days ago

Novo Nordisk Earnings Call Transcript: Q1 2026


Novo Nordisk Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 18 days ago

Novo Nordisk Quarterly report: Q1 2026


Novo Nordisk Slides: Q1 2026

May 6, 2026, 7:00 AM EDT - 18 days ago

Novo Nordisk Slides: Q1 2026


Novo CEO: 80% of Wegovy weight-loss users new

May 6, 2026, 4:48 AM EDT - 18 days ago

Novo CEO: 80% of Wegovy weight-loss users new


Novo Nordisk CEO: Aim to expand U.S. weight-loss market

May 6, 2026, 4:46 AM EDT - 18 days ago

Novo Nordisk CEO: Aim to expand U.S. weight-loss market


Novo Nordisk's first-quarter profit beats forecasts

May 6, 2026, 1:36 AM EDT - 18 days ago

Novo Nordisk's first-quarter profit beats forecasts


Novo Nordisk's weight-loss pill boom faces price war test

May 5, 2026, 3:03 AM EDT - 19 days ago

Novo Nordisk's weight-loss pill boom faces price war test


Canada approves second generic version of Ozempic

May 1, 2026, 3:50 PM EDT - 23 days ago

Canada approves second generic version of Ozempic


Hooooooold
Hooooooold May. 24 at 9:35 PM
$NVO the pill is going to be big for locations with weak cold chain storage.
0 · Reply
TradingNode
TradingNode May. 24 at 9:32 PM
$NVO A recent development from last week highlights Novo Nordisk’s expanding long-term healthcare footprint in Algeria. With support from Danish diplomacy, Novo met with Algeria’s Ministry of Health to discuss broader cooperation beyond its existing partnership with state-owned pharma company Saidal. The discussions covered diabetes and obesity prevention, early screening and diagnosis of chronic diseases, healthcare digitization (electronic medical records and telemedicine), and strengthening local healthcare infrastructure. Last year, Novo already signed a strategic agreement with Saidal focused on the production and distribution of innovative treatments, including next-generation insulins. Algeria has a population of ~48M, with an estimated 27% obesity rate, positioning it as a potentially meaningful long-term market amid rising global metabolic disease prevalence. The focus is gradually shifting from single product exposure to broader healthcare system penetration.
0 · Reply
capitalthinktank
capitalthinktank May. 24 at 2:51 PM
$NVO is increasing its collaboration with Egypt’s Healthcare Authority in preparation for Phase 2 of the country’s universal health insurance rollout. The partnership will target obesity, diabetes, fatty liver disease, and rare blood disorders such as hemophilia, while also strengthening prevention and early detection initiatives for chronic conditions. Novo and Egypt’s Healthcare Authority are further expanding training programs for physicians, nurses, and pharmacists, aligned with global treatment standards. Minya Governorate is set to be the first region in Phase 2, identified as a key focus area due to its large population and the need for greater awareness and training efforts. The two sides also reviewed ongoing hemophilia programs in Ismailia and Aswan, with plans to extend them to Luxor.
0 · Reply
MaikbestTV
MaikbestTV May. 24 at 11:50 AM
$NVO new positive bullish Novo Nordisk could be setting up for a major comeback. 🚀 Strong early demand for the new oral Wegovy pill, millions of prescriptions already, and Europe moving closer to approval. The obesity market is still massive and growing fast. If the pill keeps scaling, this could completely shift sentiment around $NVO again. Bulls are starting to come back. 👀
0 · Reply
Baxter5
Baxter5 May. 24 at 8:26 AM
$NVO nice base being built at the 44 doller
0 · Reply
JIMMYRIZZ
JIMMYRIZZ May. 24 at 6:17 AM
0 · Reply
JIMMYRIZZ
JIMMYRIZZ May. 24 at 3:43 AM
0 · Reply
clan
clan May. 23 at 10:53 PM
$MNKD $LLY $NVO Type 1 diabetic and highly-favored Indycar driver, Conor Daly, will be driving the #23 car🏎 at the 500 on Sunday afternoon. 😙🧱 A win🏁, a puff of Afrezza, and then drinking the milk🥛. For the good of all Mannkind.
0 · Reply
Hooooooold
Hooooooold May. 23 at 9:02 PM
$NVO copied from reddit post >> 6 full weeks after Foundayo’s launch (and 5.5 weeks after broad pharmacy availability), the Wegovy pill has a >97% US market share, selling 42 pills for every time Lilly sells 1. That is incredibly impressive - “winner takes it all” dynamics.
1 · Reply
Hooooooold
Hooooooold May. 23 at 6:52 PM
$NVO it would be pretty crazy if the EU blocks or delays foundayo approval a year or two.
2 · Reply
ihsvenoidea
ihsvenoidea May. 23 at 4:23 PM
$NVO no risk it, no biscuit. VK all the way!
0 · Reply
FibonacciTrader_
FibonacciTrader_ May. 23 at 2:20 PM
Conviction-style comparison setup Framing current positioning in $AMD through a historical “early entry → expansion cycle” lens based on prior asymmetric trades: $AMD current focus, positioned as the next potential multi-phase move $SOFI prior example of accumulation around $7 before expansion $SHOP early structural entry zone around $55 during re-rating phase $NVO healthcare growth positioning around $38 before continued trend $ASTS early-stage satellite infrastructure entry around $24 Identifying early dislocation phases before narrative + liquidity fully converge This approach is about consistency in spotting setups where sentiment is still forming, not already priced in
0 · Reply
DoomBot1
DoomBot1 May. 23 at 12:06 PM
1 · Reply
theirishreally
theirishreally May. 23 at 6:17 AM
$NVO by the way whatever happened the other pills from old Eli? What was it? Effectiveness? Oh well!
0 · Reply
theirishreally
theirishreally May. 23 at 6:15 AM
$NVO more good news! Expanding AI use to speed up new drugs. Not expanding the headcount as much as projected as doesn’t want to be foolhardy. The sort of company you buy for your grandchildren at these prices. They’ll chose the bestest care home for you after this!
0 · Reply
LLYBULL
LLYBULL May. 23 at 3:25 AM
$NVO Run from here as fast as you can!
1 · Reply
LLYBULL
LLYBULL May. 23 at 2:58 AM
$NVO No where to run, no where to hide if you are with nvo. Dump this rotten Hog!
0 · Reply
LLYBULL
LLYBULL May. 23 at 2:57 AM
$NVO See this article below. nvo has lost the battle everywhere. In US, LLY will not leave you crooks!
0 · Reply
LLYBULL
LLYBULL May. 23 at 2:55 AM
$NVO nvo is a joke
1 · Reply
topstockalerts
topstockalerts May. 23 at 2:52 AM
Generic versions of Wegovy and Ozempic are already available in countries like Canada and India, but the U.S. won’t see them until at least 2031–2032 due to extended pharmaceutical patent protections. The key reason is that the U.S. allows patent-term extensions—up to five additional years—under laws shaped by the Hatch-Waxman Act, effectively lengthening exclusivity beyond the standard 20 years. This delay keeps semaglutide, the active ingredient in Novo Nordisk’s drugs, under monopoly protection much longer in the U.S. than in countries where key patents have already expired. As a result, countries covering about 40% of the global population are beginning to access cheaper generics, some priced as low as $15 per month, while U.S. patients continue paying premium prices. Analysts estimate that this extended exclusivity could allow Novo Nordisk to generate roughly $146B in U.S. revenue through 2031. $NVO $LLY
1 · Reply
LLYBULL
LLYBULL May. 23 at 2:49 AM
$NVO @Pseudominds In meantime, keep eating cylindrical green shit left from Geese in parks. This will enlighten your dipshit skull with more greener geese shit.
1 · Reply
LLYBULL
LLYBULL May. 23 at 12:53 AM
$NVO @Pseudominds Most disturbed dipshit is this mental guiding people wrong here when he has no investments here, just paid to post. This dipshit empty skull full of hog shit will be playing chess with penguins there up north.
3 · Reply